Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antiemetics
Swiss pharmaceutical group announces European drug submission for palonosetron
September 1st, 2003
Helsinn Healthcare, SA, a privately owned Swiss pharmaceutical group, announced the submission of their European drug application for palonosetron through the centralized procedure that will lead to the drug approval in all European Union countries. "Palonosetron is one of the most important novelties reported in the antiemetic field in the last 10 years," said Matti Aapro, MD, oncologist at the Clinique de Genolier, near Geneva, Switzerland. "Preventing nausea and vomiting due to chemotherapy is still a challenging task for oncologists and many patients. We welcome palonosetron, a second generation of 5-HT3 receptor antagonist able to relieve patients from immediate...
Source: Health & Medicine Week (2003-09-01)
|
